This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb (BMS) has shared new long-term data from a study evaluating Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis (RMS).
Bristol Myers Squibb (BMS) has announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia (ozanimod) from the ongoing phase 3 DAYBREAK
Bristol Myers Squibb's (BMS) Zeposia (ozanimod) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with moderate-to-severe active ulcerative
The collaboration adds to BMS’ IBD portfolio, which currently includes Zeposia (ozanimod), approved for ulcerative colitis and multiple sclerosis, as well as deucravacitinib for the treatment of patients with severe ulcerative
Bristol Myers Squibb (BMS) announced that analysis from two phase 3 trials of Zeposia (ozanimod) showed that early use of the treatment demonstrated cognitive benefits in people with relapsing multiple sclerosis
The data presented at ECTRIMS 2021 reinforces the efficacy and safety profile of Zeposia (ozanimod) in patients with relapsing forms of multiple sclerosis. ... Bristol Myers Squibb has announced interim results from the phase 3 extension trial DAYBREAK,
More from news
Approximately 5 fully matching, plus 27 partially matching documents found.
The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the
treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.
Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
No results were found
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...